Forecast
The analysts' average price target is €17.68 (+66.17%). The median is €18.23 (+71.33%).
| Buy |
Â
3 |
| Hold |
Â
5 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Astria Therapeutics reports strong phase‑1b/2 data for HAE drug Navenibart
The ALPHA‑STAR study of 29 patients showed clear efficacy for Navenibart and a favorable safety profile: median reductions in HAE attack rate of 84–92% over six months and attack‑free rates of 62% and 67% in expanded cohorts. No serious adverse events or study discontinuations were reported; four non‑serious, treatment‑related events resolved quickly. Astria Therapeutics has initiated the phase‑3 ALPHA‑ORBIT study on schedule, with initial results expected in early 2027, and is conducting an open‑label long‑term extension. » More on de.investing.com
Astria Therapeutics starts phase‑3 long‑term study ORBIT‑EXPANSE for HAE therapy Navenibart
Astria Therapeutics has started the phase‑3 long‑term study ORBIT‑EXPANSE for Navenibart to prevent hereditary angioedema; participants from the approval‑relevant ALPHA‑ORBIT study can transition. The study includes a fixed dosing phase of at least six months followed by a flexible phase in which patients can receive quarterly or semiannual subcutaneous doses. In parallel, the company is developing the OX40 antibody STAR‑0310 with positive phase‑1a results, and H.C. Wainwright reaffirmed a “Buy” rating and raised the price target to $20.00. » More on de.investing.com
Astria reports positive Phase‑1a results for long‑acting OX40 antibody STAR‑0310
Astria Therapeutics reports that STAR‑0310 showed a half‑life of up to 68 days in a Phase‑1a study in healthy volunteers, dose‑proportional increases in concentrations and sustained ex‑vivo cytokine inhibition for 16–20 weeks. The drug was well tolerated at all dose levels; there were no serious treatment‑related events and only seven mild, self‑resolving adverse events. Astria plans an update to its development plans and will present the data at the EAADV congress; analyst targets range from $16 to $49. At a share price of $7.27 the balance sheet shows more cash than debt, but the company remains unprofitable. » More on de.investing.com
Financials
In the last quarter, Astria Therapeutics Aktie had revenue of €601.6K and net profit of -€26.96M
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 601.6K | - |
| Gross profit | 601.6K | - |
| Net profit | -26.96M | - |
| EBITDA | -26.96M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €654.47M |
Number of shares | 57.08M |
52-week high/low | €12.11 - €3.24 |
| Dividends | No |
Beta | 0.02 |
P/E ratio | -11.23 |
PEG ratio | 1.37 |
P/B ratio | 3.13 |
P/S ratio | 1,017.18 |
Company profile
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
| Name | Astria Therapeutics Aktie |
| CEO | Jill C. Milne |
| Headquarters | Boston,
ma USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 06/25/2015 |
| Employees | 78 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ATXS |